A more severe disease course was seen among pediatric myasthenia gravis (MG) patients with antibodies against acetylcholine receptors (AChRs) who also have antibodies against ryanodine receptors (RyR) and the titin protein, according to a new study. These children had a higher likelihood of having generalized MG (gMG) and…
News
A 44-year-old woman positive for the human immunodeficiency virus (HIV) developed myasthenia gravis (MG) after receiving treatment with antiretroviral agents. While no clear guidelines exist for treating MG in HIV-infected patients, researchers noted the woman was successfully treated with prednisone, azathioprine, and plasma exchange. According to them, this approach…
A European Medicines Agency (EMA) committee has recommended the approval of Argenx’s under-the-skin, or subcutaneous, formulation of efgartigimod as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). Argenx’s into-the-vein (intravenous) formulation of efgartigimod, sold as Vyvgart,…
Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according to data shared by its developer, Alpine Immune Sciences. Povetacicept also was tolerated well by healthy volunteers participating in a Phase 1 clinical trial. “Together, these data provide strong…
Recipharm is partnering with Ahead Therapeutics to develop a new type of therapy to reestablish immune tolerance and prevent the self-reactive immune attacks that cause myasthenia gravis (MG). “Together with our partner, we are determined to help them turn hope into reality for people living with myasthenia…
Folia Health is expanding the use of its smartphone app for gathering self-reported patient health data to people with myasthenia gravis (MG) and other neurological conditions. Patients’ daily experiences will contribute to obtaining comprehensive data on disease progression and treatment response, which are expected to contribute to improving…
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments, which can be fatal for patients in some cases, a new study found. In fact, treatment-related adverse effects were seen among more than 40% of patients in the study —…
A cell-based assay for detecting myasthenia gravis (MG)-causing antibodies in the blood results in greater diagnostic accuracy than two other antibody tests, according to data from a study in China. The cell-based assay (CBA) was superior to enzyme-linked immunoabsorbent assay (ELISA) and radioactivity radioimmunoprecipitation assay (RIPA) at detecting antibodies…
Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first therapy to win approval in the Asian nation for treating children and adolescents with this type of the autoimmune condition. The expanded use was granted by the Japanese Ministry of…
More than half of myasthenia gravis (MG) patients take more than a year to be diagnosed from symptom onset and about two-thirds feel the diagnostic process was long and/or very complicated, according to an online survey in Poland. Also, while 7 out of 10 respondents said their current treatment…
Recent Posts
- My twin’s diet changes again after a lactose intolerance diagnosis
- The dangers of misinformation in a world that craves certainty
- Being silent about my MG symptoms is like wearing a mask
- Urinary incontinence may affect about half of MG patients: Study
- New study explores when MG patients can taper immunosuppressive therapy